Fundraisings and IPOs

Date: 2017-01-06

Type of information: Grant

Company: PCI Biotech (Norway) Ultimovacs (Norway)

Investors: Innovation Norway (Norway)

Amount: NOK 500,000

Funding type: grant

Planned used: The grant will be used for exploring synergies between PCI Biotech and Ultimovacs' complementary scientific platforms for preclinical research. PCI Biotech is focusing on development of novel cancer therapies through a photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery). Ultimovacs is developing novel immunotherapy against cancer. The leading product is UV1, a synthetic peptide vaccine directed against human telomerase (hTERT).The peptide included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.

Others:

• • On January 6, 2017, PCI Biotech  and Ultimovacs announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities. The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster a Norwegian Centre of Expertise.

Therapeutic area: Cancer - Oncology

Is general: Yes